Back to search
Amyloid Cardiomyopathy, Transthyretin-Related
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Amyloid Cardiomyopathy, Transthyretin-Related trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Amyloid Cardiomyopathy, Transthyretin-Related trials you may qualify forThe MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease…
The overall objective of this DPSS is to describe the occurrence of pregnancy and maternal complications, adverse effects on the developing fetus and neonate, a…
This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with A…
This is a single center prospective study evaluating 124I-evuzumitide in patients with systemic amyloidosis. The purpose of this study is to 1) Establish the di…
This study focuses on hereditary transthyretin amyloidosis (ATTRv) with the Val50Met variant in a non endemic aerea
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a serious and life-threatening condition where a protein called transthyretin (TTR) misfolds and builds up as…
Familial amyloid neuropathies (FAP) are hereditary disease due to a mutation of the tranthyretin gene (TTR). These neuropathies are severe and life frightening.…
The aim of this study is to investigate the association between increased lifetime physical activity and the development of wild-type transthyretin amyloid card…